Apyx Medical Corporation Reaffirms FY23 Revenue Guidance Of $59M-$62M
Portfolio Pulse from Benzinga Newsdesk
Apyx Medical Corporation has reaffirmed its revenue guidance for FY23, expecting to generate between $59M and $62M.
August 10, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apyx Medical Corporation's reaffirmation of its FY23 revenue guidance could instill confidence in investors, potentially leading to a positive impact on its stock price.
Reaffirming revenue guidance is generally seen as a positive sign by investors as it indicates that the company is confident in its financial outlook. This could lead to increased investor confidence in APYX, potentially driving up its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100